Triple
T19331795
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | Fosun Pharma |
E483513
|
entity |
| Predicate | hasSubsidiary |
P254
|
FINISHED |
| Object | Shanghai Henlius Biotech |
—
|
NE NERFINISHED |
How this triple was built (3 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: Shanghai Henlius Biotech | Statement: [Fosun Pharma, hasSubsidiary, Shanghai Henlius Biotech]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Shanghai Henlius Biotech Context triple: [Fosun Pharma, hasSubsidiary, Shanghai Henlius Biotech]
-
A.
Fosun Pharma
Fosun Pharma is a major Chinese pharmaceutical and healthcare company engaged in the research, development, manufacturing, and distribution of a wide range of medical products and services.
-
B.
Shanghai Zhangjiang (Group) Co., Ltd.
Shanghai Zhangjiang (Group) Co., Ltd. is a state-backed Chinese enterprise responsible for planning, constructing, and operating Shanghai’s Zhangjiang Hi-Tech innovation and industrial clusters.
-
C.
Sinopharm
Sinopharm is a Chinese state-owned pharmaceutical company best known globally for developing and distributing inactivated COVID-19 vaccines.
-
D.
Samsung Biologics
Samsung Biologics is a South Korean biopharmaceutical company specializing in contract development and manufacturing (CDMO) of biologic drugs for global pharmaceutical and biotech firms.
-
E.
Hargreave-Rasch Biotechnologies
Hargreave-Rasch Biotechnologies is a fictional advanced biotech corporation in the Crysis video game universe, known for its cutting-edge research into alien technology and military applications.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Shanghai Henlius Biotech Target entity description: Shanghai Henlius Biotech is a Chinese biopharmaceutical company specializing in the research, development, and commercialization of biosimilar and innovative biologic medicines.
-
A.
Fosun Pharma
Fosun Pharma is a major Chinese pharmaceutical and healthcare company engaged in the research, development, manufacturing, and distribution of a wide range of medical products and services.
-
B.
Shanghai Zhangjiang (Group) Co., Ltd.
Shanghai Zhangjiang (Group) Co., Ltd. is a state-backed Chinese enterprise responsible for planning, constructing, and operating Shanghai’s Zhangjiang Hi-Tech innovation and industrial clusters.
-
C.
Sinopharm
Sinopharm is a Chinese state-owned pharmaceutical company best known globally for developing and distributing inactivated COVID-19 vaccines.
-
D.
Samsung Biologics
Samsung Biologics is a South Korean biopharmaceutical company specializing in contract development and manufacturing (CDMO) of biologic drugs for global pharmaceutical and biotech firms.
-
E.
Hargreave-Rasch Biotechnologies
Hargreave-Rasch Biotechnologies is a fictional advanced biotech corporation in the Crysis video game universe, known for its cutting-edge research into alien technology and military applications.
- F. None of above. chosen
Provenance (2 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69d8e8d13e3c81909d91d1d5ec37c095 |
completed | April 10, 2026, 12:10 p.m. |
| NER | Named-entity recognition | batch_69e616422fa08190bf4bde4312ec7cf3 |
completed | April 20, 2026, 12:04 p.m. |
Created at: April 10, 2026, 1:33 p.m.